MA52748A - Produit immunogène comprenant il-4 et/ou il-13 pour le traitement de troubles associés à l'expression ou à l'activité aberrante de l'il-4 et/ou de l'il-13 - Google Patents

Produit immunogène comprenant il-4 et/ou il-13 pour le traitement de troubles associés à l'expression ou à l'activité aberrante de l'il-4 et/ou de l'il-13

Info

Publication number
MA52748A
MA52748A MA052748A MA52748A MA52748A MA 52748 A MA52748 A MA 52748A MA 052748 A MA052748 A MA 052748A MA 52748 A MA52748 A MA 52748A MA 52748 A MA52748 A MA 52748A
Authority
MA
Morocco
Prior art keywords
expression
treatment
disorders associated
aberrant activity
immunogen including
Prior art date
Application number
MA052748A
Other languages
English (en)
Inventor
Pierre Bruhns
Noémie Caillot
Garcìa Eva Conde
Géraldine Grouard-Vogel
Laurent Reber
Bertrand Romain
Vincent Serra
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut, Neovacs filed Critical Inst Nat Sante Rech Med
Publication of MA52748A publication Critical patent/MA52748A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052748A 2018-05-29 2019-05-29 Produit immunogène comprenant il-4 et/ou il-13 pour le traitement de troubles associés à l'expression ou à l'activité aberrante de l'il-4 et/ou de l'il-13 MA52748A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677290P 2018-05-29 2018-05-29
EP18305651.4A EP3574915A1 (fr) 2018-05-29 2018-05-29 Produit immunogène comprenant de l'il-4 et/ou de l'il-13 pour traiter des troubles associés à une expression ou une activité aberrantes de l'il-4 et/ou de l'il-13
PCT/EP2019/050154 WO2019228674A1 (fr) 2018-05-29 2019-01-04 Produit immunogène comprenant l'il-4 et/ou l'il-13 pour le traitement de troubles associés à l'expression ou à l'activité aberrante de l'il-4 et/ou de l'il-13

Publications (1)

Publication Number Publication Date
MA52748A true MA52748A (fr) 2021-06-02

Family

ID=62631036

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052748A MA52748A (fr) 2018-05-29 2019-05-29 Produit immunogène comprenant il-4 et/ou il-13 pour le traitement de troubles associés à l'expression ou à l'activité aberrante de l'il-4 et/ou de l'il-13

Country Status (15)

Country Link
US (2) US12059457B2 (fr)
EP (3) EP3574915A1 (fr)
JP (2) JP7291729B2 (fr)
KR (2) KR20250156179A (fr)
CN (1) CN112423784B (fr)
AU (2) AU2019276173B2 (fr)
BR (1) BR112020024308A2 (fr)
CA (1) CA3101702A1 (fr)
CU (1) CU20200091A7 (fr)
IL (2) IL278898B2 (fr)
MA (1) MA52748A (fr)
MX (2) MX421649B (fr)
SG (1) SG11202011528UA (fr)
WO (2) WO2019228674A1 (fr)
ZA (1) ZA202007264B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212598A1 (fr) 2019-04-19 2020-10-22 Synerkine Pharma B.V. Protéine de fusion comprenant de l'il13
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
CA3229324A1 (fr) * 2021-08-20 2023-02-23 Beatrice DROUET Vaccins a arnm comprenant de l'arn il-4 et/ou il-13 et utilisations associees

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207A (en) 1849-03-20 Improved spriing snap-hook
US646A (en) 1838-03-21 Improvement in furnaces for smelting iron with anthracite
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (fr) 1991-12-23 1993-07-08 Michael Zoche Moteur avec deshuileur
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
AU2002363382B2 (en) 2001-11-07 2007-07-19 Cytos Biotechnology Ag Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases
WO2004019975A2 (fr) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccin
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
EP1947116B1 (fr) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Acides nucléiques exprimés par action différentielle dans la barrière hématoencéphalique sous des conditions inflammatoires
CN101120101A (zh) * 2004-04-13 2008-02-06 阿尔扎公司 多联疫苗透皮释放的装置和方法
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CN100558747C (zh) * 2006-04-06 2009-11-11 海南天源康泽医药科技有限公司 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
AU2012236403B2 (en) 2011-03-29 2016-08-04 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
WO2012136739A1 (fr) * 2011-04-07 2012-10-11 Neovacs Méthode de traitement d'états liés à l'ifnalpha
WO2012151343A1 (fr) * 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Dérivés de pentylènetétrazole
KR101895768B1 (ko) * 2011-06-01 2018-09-07 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
EP2659906A1 (fr) * 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013179302A1 (fr) 2012-05-15 2013-12-05 Rajesh Shah Formulation anti-inflammatoire
DK2668959T3 (en) * 2012-05-31 2015-01-26 Innavirvax Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
MX2017001638A (es) * 2014-08-05 2017-04-27 Glaxosmithkline Biologicals Sa Molecula portadora para antigenos.
CN109890408A (zh) * 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法

Also Published As

Publication number Publication date
CN112423784B (zh) 2024-09-20
CA3101702A1 (fr) 2019-12-05
CU20200091A7 (es) 2021-07-02
KR20210022571A (ko) 2021-03-03
US12059457B2 (en) 2024-08-13
BR112020024308A2 (pt) 2021-02-23
EP3801603A2 (fr) 2021-04-14
EP3574915A1 (fr) 2019-12-04
WO2019229153A3 (fr) 2020-02-20
AU2019276173A1 (en) 2020-12-17
KR102871378B1 (ko) 2025-10-16
IL278898B1 (en) 2024-02-01
JP7291729B2 (ja) 2023-06-15
CN112423784A (zh) 2021-02-26
MX2020012925A (es) 2021-08-11
WO2019228674A1 (fr) 2019-12-05
KR20250156179A (ko) 2025-10-31
AU2025204082A1 (en) 2025-06-26
JP2021525726A (ja) 2021-09-27
MX2024012944A (es) 2024-12-06
SG11202011528UA (en) 2020-12-30
US20210205427A1 (en) 2021-07-08
ZA202007264B (en) 2025-04-30
IL309932A (en) 2024-03-01
AU2019276173B2 (en) 2025-10-23
IL278898A (en) 2021-01-31
MX421649B (es) 2025-03-14
WO2019229153A2 (fr) 2019-12-05
US20250025541A1 (en) 2025-01-23
IL278898B2 (en) 2024-06-01
JP2023110045A (ja) 2023-08-08
EP4144366A1 (fr) 2023-03-08

Similar Documents

Publication Publication Date Title
MA54877A (fr) Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
MA50786A (fr) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3927705A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles neurodégénératifs
EP3820537A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP3989992A4 (fr) Compositions thérapeutiques et méthodes d'utilisation d'interventions basées sur le microbiome modulant la sérotonine pour traiter des maladies ou des troubles liés à la sérotonine
EP3448389A4 (fr) Composés de quinazoline et d'indole destinés au traitement de troubles médicaux
MA56047A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
EP3606520A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
EP3484577A4 (fr) Procédés et systèmes de traitement de troubles pelviens et d'affections douloureuses
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3615521A4 (fr) Procédés d'amélioration de la mémoire et de la cognition, et de traitement des troubles de la mémoire et des troubles cognitifs
EP3692171A4 (fr) Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, élément a5, pour le traitement et le diagnostic des troubles de l'humeur
MA53739A (fr) Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
EP3707275A4 (fr) Recommandations relatives au dosage et à la variété destinées au traitement d'états pathologiques à l'aide de cannabis
MA52748A (fr) Produit immunogène comprenant il-4 et/ou il-13 pour le traitement de troubles associés à l'expression ou à l'activité aberrante de l'il-4 et/ou de l'il-13
EP3743091A4 (fr) Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf
EP3681477A4 (fr) Méthode et composition améliorée pour le traitement d'états pathologiques, de maladies ou de troubles sensibles aux triterpènes
MA51015A (fr) Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci
EP3504204A4 (fr) Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
EP3802568A4 (fr) Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés
EP3806865A4 (fr) Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels
EP3932486A4 (fr) Composition de traitement de troubles de la coagulation du sang et/ou du complément